Search results for: 'test of use copyright'

Clinical genomics regained significance during the pandemic with the development of the mRNA COVID-19 vaccine, and several non-invasive at-home test kits; an unprecedented feat in recent times. Genomics will take center stage, as large genome sequencing and research will continuously create data for new therapeutics. Artificial Intelligence (AI) an...

Since the onset of the COVID-19 pandemic, molecular diagnostics mergers/acquisition transactions and product launches for infectious disease testing are indicating a pivot toward a new direction or an enhancement of portfolios. The emergence of saliva sample testing and the transition to PCR-based syndromic and direct-to-consumer testing for respir...

22 Oct 2015  |  North America  |  Market Research

Analysis of the US Clinical Laboratories Market

Decentralization will Significantly Increase Retail Setting Test Volume by 2017

Infographics

×

This research service evaluates the US clinical laboratories market. The analysis provides extensive understanding of test distribution in independent laboratories (reference and specialized), physician office laboratories, hospital-based labs, and others including retail clinics and mobile diagnostic centers. The study covers the potential impact ...

This research service on the global pharma extractables and leachables (E&L) testing market addresses the market sizing, emerging trends, and technologies, and provides a snapshot of the key participants in the market. The base year for the deliverable is 2015 while forecasts have been provided from 2016 to 2020. The pharma E&L testing market is ...

01 Jul 2016  |  Europe  |  Market Research

Western Europe Point-of-Care Testing (POCT) Market

Infographics

×

Point-of-care testing is an integral part of the IVD market that is rapidly evolving into a preferred testing mode in the EU region. POCT is a segment that presents growth opportunities for a cross-section of players, ranging from OEMs to data integrators to technology vendors. The stakeholders need to be abreast of the challenges posed by the indu...

23 Jun 2016  |  North America  |  Market Research

Growth Opportunities in the US Point-of-care Testing Market

Digital Health Meets Point of Care—Emergence of Mobile Molecular Diagnostics

Infographics

×

The US point-of-care testing (POCT) study provides an extensive analysis for 13 segments: hematology, urinalysis, infectious disease, cardiac, HbA1c, glucose, fecal occult blood test/fecal immunochemical test (FOBT/FIT), coagulation PT/INR, coagulation APTT/ACT, cholesterol, pregnancy, drugs of abuse, and blood gas and electrolytes. Key trends and ...

03 Oct 2022  |  Global  |  Market Research

Global Prenatal Genetic Testing—Forecast to 2026

Innovation Culture in Screening Drives Prenatal Genetic Testing Growth and Makes it Accessible to More Patients

Infographics

×

New technological advances in prenatal genetic testing include the enhancement of the next-generation sequencing (NGS) technology, chromosomal microarray analysis (CMA) tool, and PCR TaqMan. These improve precision and specificity in genome profiling, augment the efficiency and reliability of testing, and streamline workflow. The study will help...

23 Aug 2022  |  North America  |  Frost Radar

Frost Radar™: US Liquid Biopsy, 2022

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

The oncology space is maturing rapidly. With the arrival of blood-based assays for cancer screening and the emphasis on early detection, the liquid biopsy segment is seeing increased consolidation and high-impact acquisitions, such as Illumina and GRAIL, Exact Sciences and Thrive Earlier Detection, and Roche Foundation Medicine and Lexent Bio. Comp...

In 2003, the first human genome sequence was produced, with a production cost between $500 million and $1 billion. However, since 2008, when next-generation sequencing (NGS) approaches entered the research setting, there has been a significant decline in sequencing costs. These approaches allow either the whole genome (via whole-genome sequencing [...